Skip to main content

Advertisement

SpringerLink
Log in

Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy

  • Biomarkers of Heart Failure (W H W Tang, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Heart failure is a growing global public health problem. With the aging population, increased risk factors for heart failure development, and better survival after myocardial infarction, the prevalence is only expected to increase in the coming years. Although existing therapies have improved the clinical course of heart failure patients, new approaches are urgently needed to enhance quality of life and reduce morbidity and mortality. However, there has been little progress in the treatment of chronic heart failure in the past decade with only two new drugs approved by the US FDA over this time. Better understanding of the neurohormonal axis of heart failure has lead to the development of LCZ696, a first-in-class novel agent that acts as an angiotensin receptor blocker and neprilysin inhibitor. In the PARADIGM-HF study, LCZ696 was superior to an angiotensin-converting enzyme inhibitor in reducing mortality and HF hospitalizations and improving quality of life across a broad spectrum of symptomatic patients with heart failure with reduced ejection fraction. While evaluation of long-term effects is still needed, the completed trials on LCZ696 demonstrate that the drug is generally well-tolerated with a safe side effect profile. LCZ696 should be strongly considered as a favorable alternative to angiotensin converting enzyme inhibitors and angiotensin receptor blockers in appropriate heart failure patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lillyblad MP. Dual angiotensin receptor and neprilysin inhibition with sacubitril/valsartan in chronic systolic heart failure: understanding the new PARADIGM. Ann Pharmacother. 2015;11:1237–51.

    Article  Google Scholar 

  2. Mills J, Vardeny O. The role of neprilysin inhibitors in cardiovascular disease. Curr Heart Fail Rep. 2015;6:389–94.

    Article  Google Scholar 

  3. Stingo AJ, Clavell AL, Aarhus LL, Burnett Jr JC. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol. 1992;262:H308–12.

    CAS  PubMed  Google Scholar 

  4. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8.

    Article  CAS  PubMed  Google Scholar 

  5. Vardeny O, Miller R, Solomon S. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. J Am Coll Cardiol Heart Fail. 2015;6:663–70. Vardeny et al. authored the above comprehensive and informative review regarding the pathophysiology of natriuretic peptides and the pharmacology and clinical trials for neprilysin inhibition including LCZ696.

    Google Scholar 

  6. Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, et al. Circulating c-type natriuretic peptide and its relationship to cardiovascular disease in the general population. Hypertension. 2015;65(6):1187–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Owens AT, Brozena SC, Jessup M. New management strategies in heart failure. Circ Res. 2016;118(3):480–95.

    Article  CAS  PubMed  Google Scholar 

  8. Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;3:355–60.

    Article  Google Scholar 

  9. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.

    Article  Google Scholar 

  10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.

    Article  Google Scholar 

  11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.

    Article  Google Scholar 

  12. The Val-HEFT Investigators. A randomized trial of angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.

    Article  Google Scholar 

  13. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–71.

    Article  CAS  PubMed  Google Scholar 

  14. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.

    Article  PubMed  Google Scholar 

  15. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–6.

    Article  CAS  PubMed  Google Scholar 

  16. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.

    Article  CAS  PubMed  Google Scholar 

  17. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.

    Article  Google Scholar 

  18. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.

    Article  Google Scholar 

  19. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.

    Article  CAS  PubMed  Google Scholar 

  20. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

    Article  CAS  PubMed  Google Scholar 

  21. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett Jr JC. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol. 1998;275:F410–4.

    CAS  PubMed  Google Scholar 

  22. Bayes-Genis A, Barallat J, Galan A, de Antonio M, Domingo M, Zamora E, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65(7):657–65. Bayes-Genis et al. performed a prospective study that showed high levels of neprilysin were associated with a worse heart failure prognosis with significant composite endpoint of CV death or HF hospitalization and primary end point of CV mortality. This is one of the first studies to demonstrate that heart failure patients have elevated levels of neprilysin and its associated poor prognosis.

    Article  CAS  PubMed  Google Scholar 

  23. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995;26:1160–6.

    Article  CAS  PubMed  Google Scholar 

  24. McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999;1:79–84.

    Article  Google Scholar 

  25. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet. 2000;356(9230):615–20.

    Article  CAS  PubMed  Google Scholar 

  26. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–6.

    Article  CAS  PubMed  Google Scholar 

  27. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103–11.

    Article  CAS  PubMed  Google Scholar 

  28. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.

    Article  CAS  PubMed  Google Scholar 

  29. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.

    Article  CAS  PubMed  Google Scholar 

  30. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.

    Article  CAS  PubMed  Google Scholar 

  31. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062–73. The above study is the focus of the review and is a multi-center, randomized, placebo control, double-blind study evaluating LCZ696 therapy in patients with heart failure of reduced ejection fraction. It is a highly significant landmark trial demonstrating the substantial mortality and morbidity risk reduction in patients treated with LCZ696 compared to enalapril.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Jessup M. Neprilysin inhibition – a novel therapy for heart failure. N Engl J Med. 2014;271:1062–4.

    Article  Google Scholar 

  33. Feldman AM, Haller JA, DeKosky ST. Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA. 2016;315(1):25–6.

    Article  CAS  PubMed  Google Scholar 

  34. New drug application approval letter. US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207620Orig1s000ltr.pdf. Accessed November 30, 2015.

  35. Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373(23):2289–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of California, San Diego, 9444 Medical Center Drive, La Jolla, CA, 92037-7411, USA

    Ruth Hsiao & Barry Greenberg

Authors
  1. Ruth Hsiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barry Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barry Greenberg.

Ethics declarations

Conflict of Interest

Ruth Hsiao declares that she has no conflict of interest.

Barry Greenberg has received consulting and speaking fees from Novartis

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Biomarkers of Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hsiao, R., Greenberg, B. Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy. Curr Heart Fail Rep 13, 172–180 (2016). https://doi.org/10.1007/s11897-016-0297-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-016-0297-5

Keywords

Search

Navigation